# The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL

> **NCT03509961** · PHASE2 · RECRUITING · sponsor: **Pediatric Transplantation & Cellular Therapy Consortium** · enrollment: 95 (estimated)

## Conditions studied

- B-cell Acute Lymphoblastic Leukemia

## Interventions

- **DIAGNOSTIC_TEST:** NGS-MRD
- **DRUG:** Myeloablative allogeneic HCT with a non-TBI conditioning regimen

## Key facts

- **NCT ID:** NCT03509961
- **Lead sponsor:** Pediatric Transplantation & Cellular Therapy Consortium
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2018-08-29
- **Primary completion:** 2025-07-01
- **Final completion:** 2026-07-01
- **Target enrollment:** 95 (ESTIMATED)
- **Last updated:** 2025-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03509961

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03509961, "The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03509961. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*